GuidelineEuropean radiology2018
Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency.
Guideline in European radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 106 citations in OpenAlex.
- Pharmacokinetics, Elimination and Dialyzability of HRS-9231 in Patients with Varying Degrees of Renal Impairment.Clinical pharmacokinetics · 2026Article
- Magnetite nanodiscs as vortex-enhanced MRI contrast agents: a novel approach in medical imaging.Nanoscale advances · 2026Article
- Development and validation of a nomogram combining PI-RADS v2.1 and clinical indicators for the diagnosis of prostate cancer in patients with PSA ≤ 20 ng/mL.Abdominal radiology (New York) · 2026Article
- Long-term behaviour of non-functioning pituitary microadenomas: experience from a tertiary care centre in Romania.Frontiers in endocrinology · 2025Article
- A Hexanuclear Gadolinium(III)-Based Nanoprobe for Magnetic Resonance Imaging of Tumor Apoptosis.ACS applied nano materials · 2024Article
- Medicinal Chemistry of Drugs withJournal of medicinal chemistry · 2024Review
- Safe and Informed Use of Gadolinium-Based Contrast Agent in Body Magnetic Resonance Imaging: Where We Were and Where We Are.Journal of clinical medicine · 2024Review
- Toxicity Mechanisms of Gadolinium and Gadolinium-Based Contrast Agents-A Review.International journal of molecular sciences · 2024Review
- Article
- Ten years of gadolinium retention and deposition: ESMRMB-GREC looks backward and forward.European radiology · 2024Review
- Gadolinium contrast agents- challenges and opportunities of a multidisciplinary approach: Literature review.European journal of radiology open · 2023Review
- Brain deposition of gadobutrol in children-a cross-sectional and longitudinal MRI T1 mapping study.European radiology · 2023Article
- An Unenhanced Breast MRI Protocol Based on Diffusion-Weighted Imaging: A Retrospective Single-Center Study on High-Risk Population for Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Article
- An Electrolyte-Gated Graphene Field-Effect Transistor for Detection of Gadolinium(III) in Aqueous Media.Biosensors · 2023Article
- Does Gadolinium Deposition Lead to Metabolite Alteration in the Dentate Nucleus? An MRS Study in Patients with MS.AJNR. American journal of neuroradiology · 2022Article
- Investigating the Role of Sulfate Groups for the Binding of GdChemMedChem · 2022Article
- To Contrast or Not to Contrast? On the Role of Contrast Enhancement in Hand MRI Studies of Patients with Rheumatoid Arthritis.Diagnostics (Basel, Switzerland) · 2022Article
- Nanotechnology as a Versatile Tool forPharmaceutics · 2022Review
- L-EGCG-Mn nanoparticles as a pH-sensitive MRI contrast agent.Drug delivery · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) earlier this year recommended to suspend some marketing authorisations for Gadolinium Containing Contrast Agents (GCCAs) based on linear chelators due to the potential risk of gadolinium retention in the human body. These recommendations have recently been re-evaluated by EMA's Committee for Medicinal Products for Human Use (CHMP), and confirmed the final opinion of the European Medicines Agency. This editorial provides an overview of the available GCCAs and summarises the recent evidence of gadolinium retention. Moreover, a critical appraisal of the strengths and limitations of the scientific evidence currently available on gadolinium retention is given. KEY POINTS: • EMA recommended suspension of some EU marketing authorisations of four linear GCCAs. • Brain MRI findings indicating gadolinium retention have been confirmed by mass spectrometry. • Current scientific evidence for gadolinium retention has several methodological limitations. • No clear clinical evidence exists indicating that gadolinium retention causes neurotoxicity. • Long-term safety of GCCAs, however, remains unclear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.